Therapeutic Nuclear Medicine

Front Matter....Pages i-xviii
A Historical Perspective on the Use of Radionuclides for Therapy....Pages 3-9
Therapeutic Radionuclides: Production, Physical Characteristics, and Applications....Pages 11-50
Rhenium-188 Generator-Based Radiopharmaceuticals for Therapy....Pages 51-81
Generator-Based Radiopharmaceuticals for PET Dosimetry Before, During, and After Endoradiotherapy....Pages 83-94
Cyclotron-Based Radiopharmaceuticals for Nuclear Medicine Therapy....Pages 95-103
Peptides for Nuclear Medicine Therapy: Chemical Properties and Production....Pages 105-123
Antibodies for Nuclear Medicine Therapy....Pages 125-138
Selective High Affinity Ligands: A New Class of Targeting Agents for Cancer Imaging and Therapy....Pages 139-150
Inorganic Radionuclides for Nuclear Medicine Therapy....Pages 151-163
Pharma Considerations for Timely Development of Therapeutic Radiopharmaceuticals....Pages 165-171
Economic and Industrial Considerations for Marketing of Therapeutic Radiopharmaceuticals....Pages 173-184
Radioimmunotherapy of Brain Tumors....Pages 187-198
Radiopeptide Therapy of Brain Tumors....Pages 199-205
Intracavitary Use of Radionuclides and Treatment of Meningiomas....Pages 207-214
Radio-Tympano-Sinu-Orthesis as a Treatment Option in Chronic Otitis Media and Paranasal Mucositis....Pages 215-221
Sodium Iodide Symporter in Thyroid Carcinoma....Pages 225-232
Gene Expression Analysis by DNA Microarray in Papillary and Follicular Differentiated Thyroid Cancer....Pages 233-244
Ablation Therapy with Radioiodine in Adults and Children with Differentiated Thyroid Cancer....Pages 245-258
Redifferentiation Therapy in Thyroid Cancer....Pages 259-268
Maximal Safe Dose Method of I-131 in the Management of Recurrent/Metastatic Differentiated Thyroid Carcinoma....Pages 269-274
Therapeutic Strategy of Papillary Microcarcinoma of the Thyroid Gland: A Nuclear Medicine Perspective....Pages 275-281
UICC Classifications 1997, 2002 and 2009: What is the Impact on Thyroid Cancer Mangement?....Pages 283-287
Radioiodine Remnant Ablation: A Critical Review....Pages 289-300
Follow-up of Thyroid Cancer Patients and Treatment of Distant Metastases....Pages 301-314
Medullary Thyroid Carcinoma....Pages 315-321
Treatment of Progressive Dedifferentiated and Medullary Thyroid Cancer with Radiolabeled Somatostatin Analogs....Pages 323-332
Radioiodine Therapy of Hyperthyroidism (Toxic Goiter, Hyperfunctioning Nodule) and Non-Toxic Goiter: Procedures and Guidelines....Pages 335-346
Radioiodine Therapy of Hyperthyroidism in Graves’ Disease....Pages 347-358
Radioembolization: Concepts and Procedures....Pages 361-377
Radioembolization: Clinical Results Hepatocellular Carcinoma....Pages 379-383
Radioembolization (Yttrium-90 Microspheres) for Metastatic Hepatic Malignancies....Pages 385-392
Rhenium-188 Lipiodol for the Treatment of Hepatocellular Carcinoma (HCC)....Pages 393-404
New Approaches: Combined Local and Multimodal Strategies in the Treatment of Complex Neuroendocrine Liver Metastases....Pages 405-420
Radiolabelled Bisphosphonates for Bone Pain Palliation....Pages 423-431
Radionuclide Therapy of Bone Metastases Using Rhenium-188 Hydroxyethylidene Diphosphonate....Pages 433-445
Treatment of Osteoblastic Skeletal Metastases by the Alpha-Emitting Bone-Seeker Radium-223....Pages 447-457
Radionuclide Therapy of Inflammatory Joint Diseases (Radiation Synovectomy, Radiosynoviorthesis)....Pages 459-493
Radionuclide Therapy for Bleeding Joints in Hemophilia....Pages 495-502
Non-Hodgkin Lymphoma: Radioimmunotherapy Using Iodine-131 Labeled Murine Anti-CD20 Antibodies ( 131 I-Tositumomab and Tositumomab, “Bexxar”)....Pages 505-525
Treatment of Lymphoma with 131 I-Chimeric Monoclonal Antibodies....Pages 527-533
Non-Hodgkin’s Lymphoma High Dose Therapy....Pages 535-542
Yttrium-90 Labelled Anti-CD20 Radioimmunotherapy with Stem Cells Support....Pages 543-550
Fractionated Radioimmunotherapy of Non-Hodgkin Lymphoma with 90-Y-Labeled Anti-CD22 Antibody, Epratuzumab Tetraxetan....Pages 551-556
Targeted Alpha Particle Therapy of Peritoneal Carcinomas....Pages 557-567
I-131 Meta Iodobenzylguanidine Therapy....Pages 571-581
Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors Expressing Somatostatin Receptors....Pages 583-603
Radioimmunotherapy of Tumors: Pretargeting with Bispecific Antibodies....Pages 607-615
Targeted Radionuclide Therapy of Prostate Cancer....Pages 617-628
Radioimmunotherapy of Neuroblastoma....Pages 629-638
Radioimmunotherapy in Metastatic Colorectal Cancer....Pages 639-661
Radioimmunotherapy of Renal Cancer....Pages 663-668
Myeloablative Radioimmunotherapy in Conditioning of Acute Leukemia, MDS, and Multiple Myeloma Prior to Hematological Stem Cell Transplantation....Pages 669-683
Endovascular Brachytherapy to Prevent Restenosis After Percutaneous Coronary Intervention....Pages 687-701
Locoregional Radionuclide Therapy of Primary and Metastatic Cancers....Pages 703-715
Radionuclide Therapy for Skin Malignancies....Pages 717-724
Epidermal Radionuclide Therapy: Dermatological High-Dose-Rate Brachytherapy for the Treatment of Basal and Squamous Cell Carcinoma....Pages 725-734
Patient-Specific Dosimetry, Radiobiology, and the Previously-Treated Patient....Pages 737-745
Nuclear Medicine Dose Assessment....Pages 747-757
Monte Carlo Methods in Nuclear Medicine....Pages 759-768
Dosimetry for Peptide Receptor Radionuclide Therapy....Pages 769-779
Comparison Between β -Emitting Isotopes and α -Emitters Regarding Their Effects on Cancer Cells....Pages 781-788
Hormesis by Low Dose Radiation Effects: Low-Dose Cancer Risk Modeling Must Recognize Up-Regulation of Protection....Pages 789-805
Animal Models for Developing Radiopharmaceuticals for Therapy....Pages 807-815
Dosimetry in Accidental Radiation Exposure....Pages 817-833
Potential Impact of Radiation Biology in Radiation Protection in Nuclear Medicine and Corresponding Regulatory Issues....Pages 835-842
Radiation Protection of Staff and Public....Pages 843-852
Effects of Music on the Psyche of Neuroendocrine Tumour Patients Undergoing Peptide Receptor Radionuclide Therapy....Pages 853-864
The Use of Dosimetry in the Planning of Patient Therapy....Pages 867-877
PET for Radiotherapy Planning....Pages 879-890
Hypoxia Imaging for Radiation Therapy Planning....Pages 891-900
Chemotherapy Combined with Radionuclide Therapy....Pages 901-908
Role of Surgery in a Multidisciplinary Approach....Pages 909-916
PET for Measuring Therapy Response After Radionuclide Therapy....Pages 917-929
Developing Probes for Molecular Imaging....Pages 931-940
Back Matter....Pages 941-951